Overview
Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare form of adrenal hyperplasia characterized by the presence of large, bilateral adrenal nodules, often associated with autonomous cortisol secretion. This condition can lead to a spectrum of endocrine and metabolic disturbances, including hypertension, glucose intolerance, and dyslipidemia, significantly impacting patients' cardiovascular health and quality of life. PBMAH predominantly affects adults, with a notable female predominance observed in some studies. Understanding and managing PBMAH is crucial in day-to-day practice due to its potential to cause severe cardiometabolic complications if left untreated 1.Pathophysiology
PBMAH arises from genetic mutations or acquired alterations that disrupt normal adrenal cell regulation, leading to autonomous hormone production, particularly cortisol. The underlying molecular mechanisms often involve mutations in genes such as PRKACA, which encodes the catalytic subunit of protein kinase A (PKA), a key regulator of cortisol synthesis. These genetic alterations result in constitutive activation of the PKA pathway, independent of normal hormonal feedback mechanisms. Consequently, adrenal cells continuously produce cortisol despite normal or elevated levels in the circulation, leading to hypersecretion and associated metabolic derangements. The chronic exposure to excess cortisol contributes to the development of hypertension, insulin resistance, and dyslipidemia, reflecting the multifaceted impact on cardiometabolic health 1.Epidemiology
The exact incidence and prevalence of PBMAH remain uncertain due to its rarity and diagnostic challenges. However, studies suggest that PBMAH is relatively uncommon, with estimates ranging from a few cases per million individuals. The condition predominantly affects middle-aged adults, with a female-to-male ratio often observed around 2:1 to 3:1. Geographic distribution does not appear to show significant variations, but specific risk factors such as genetic predispositions may influence its occurrence. Trends over time indicate a gradual increase in recognition, likely due to advancements in diagnostic imaging and hormonal assays. Nonetheless, large-scale epidemiological studies are still needed to establish more definitive prevalence rates and risk factor associations 1.Clinical Presentation
Patients with PBMAH typically present with a constellation of symptoms reflecting the underlying hormonal imbalances. Common manifestations include persistent hypertension, often resistant to conventional antihypertensive therapy, and metabolic disturbances such as obesity, glucose intolerance, and dyslipidemia. Additional symptoms may encompass fatigue, muscle weakness, and menstrual irregularities in women. Red-flag features that warrant urgent evaluation include severe uncontrolled hypertension, acute adrenal insufficiency (rare but possible post-surgery), and signs of Cushingoid features like central obesity, striae, and purple striae on the abdomen. Early recognition of these symptoms is crucial for timely intervention to prevent long-term complications 1.Diagnosis
The diagnosis of PBMAH involves a comprehensive approach combining clinical evaluation, biochemical testing, and imaging studies. Key diagnostic steps include:Clinical Evaluation: Detailed history focusing on symptoms of hypertension, metabolic disturbances, and signs of Cushingoid features.
Biochemical Testing:
- 24-hour Urinary Free Cortisol (UFC): Elevated levels (typically > 100 μg/24h) suggest hypercortisolism.
- Low-Dose Dexamethasone Suppression Test (LDDST): Failure to suppress cortisol levels (cortisol > 5 μg/dL at 24 hours) indicates autonomous cortisol production.
- Fasting Blood Glucose and HbA1c: Elevated levels (HbA1c ≥ 6.5%) suggest impaired glucose metabolism.
- Lipid Profile: Elevated LDL cholesterol and triglycerides, with low HDL cholesterol, indicative of dyslipidemia.
Imaging:
- CT or MRI Adrenals: Bilateral macronodular adrenal enlargement is characteristic.
- MRI with Dotatate (SSTR Scans): Useful for confirming autonomous cortisol production and assessing adrenal nodules.Differential Diagnosis:
Ectopic ACTH Syndrome: Elevated ACTH levels differentiate from PBMAH where ACTH is typically suppressed.
Adrenal Adenomas: Unilateral involvement and often normal ACTH levels help distinguish.
Medication-Induced Hypertension: Review of patient's medication history can rule out secondary causes.
Obstructive Sleep Apnea: Consider in patients with resistant hypertension and obesity 1.Management
Surgical Management
First-Line:
Adrenalectomy: Recommended for patients with significant cardiometabolic comorbidities or those with uncontrolled hypertension despite medical therapy.
- Indications: Persistent hypertension, glucose intolerance, dyslipidemia unresponsive to medical management.
- Outcomes: Significant improvements in blood pressure control, glucose metabolism, and lipid profiles post-surgery 1.Medical Management
First-Line:
Mineralocorticoid Antagonists (e.g., Spironolactone): For managing hypertension and hypokalemia.
- Dose: Typically 50-100 mg/day, titrated based on response and side effects.
- Monitoring: Regular serum potassium levels and renal function tests.
Glucose-Lowering Agents: Metformin for insulin resistance, consider insulin or other agents if necessary.
- Dose: Metformin 500-1000 mg twice daily, adjusted based on tolerance and glycemic control.
- Monitoring: HbA1c every 3-6 months, with adjustments as needed.Second-Line:
Dexamethasone Therapy: For milder cases or those unsuitable for surgery.
- Dose: Low-dose (e.g., 0.5-1 mg nightly).
- Monitoring: Regular assessment of cortisol levels and clinical response.
Statins: For managing dyslipidemia.
- Dose: Atorvastatin 20-80 mg/day, adjusted based on lipid profile response.
- Monitoring: Periodic lipid profile checks.Contraindications:
Adrenalectomy: Absolute contraindications include severe comorbidities precluding surgery, such as advanced cardiovascular disease.
Dexamethasone: Avoid in patients with depression or cognitive impairment due to potential side effects.Complications
Acute Complications
Adrenal Insufficiency: Rare but possible post-adrenalectomy, requiring lifelong steroid replacement therapy.
Hypokalemia: Common with mineralocorticoid antagonists, necessitating potassium supplementation.Long-Term Complications
Cardiovascular Disease: Persistent hypertension and dyslipidemia increase risk of coronary artery disease, stroke, and heart failure.
Diabetes Mellitus: Chronic hypercortisolism can progress to overt diabetes, requiring intensified glycemic control strategies.
Osteoporosis: Long-term glucocorticoid exposure can lead to bone density loss, necessitating bone health monitoring and interventions.Referral Triggers:
Persistent uncontrolled hypertension despite optimal medical therapy.
Acute adrenal insufficiency post-surgery.
Complex metabolic derangements requiring multidisciplinary care 1.Prognosis & Follow-Up
The prognosis of PBMAH varies based on the effectiveness of management strategies. Patients who undergo successful adrenalectomy often experience significant improvements in cardiometabolic parameters, leading to better long-term outcomes. Key prognostic indicators include initial severity of comorbidities and adherence to post-treatment monitoring. Recommended follow-up intervals include:Initial Follow-Up: 3-6 months post-treatment to assess immediate response and adjust medications.
Subsequent Monitoring: Annually for blood pressure, glucose levels, lipid profiles, and overall metabolic health.
Imaging Follow-Up: Periodic imaging (every 2-3 years) to monitor adrenal status post-surgery.Regular monitoring helps in early detection and management of potential complications, ensuring optimal patient outcomes 1.
Special Populations
Pregnancy
Management Challenges: Balancing the need for cortisol during pregnancy while managing hypercortisolism.
Recommendations: Close monitoring of both maternal and fetal well-being, possibly adjusting glucocorticoid therapy under expert guidance.Pediatrics
Incidence: Rare, but genetic predispositions may play a role.
Approach: Early diagnosis and multidisciplinary care focusing on growth, development, and metabolic health.Elderly
Considerations: Increased risk of comorbidities and polypharmacy complicating management.
Strategies: Tailored treatment plans with careful monitoring of drug interactions and side effects.Comorbidities
Cardiovascular Disease: Prioritize blood pressure control and lipid management.
Diabetes: Intensive glycemic control strategies alongside cortisol management.Specific ethnic risk groups are not extensively detailed in the provided sources, but genetic predispositions may vary, warranting tailored genetic counseling and screening in relevant populations 1.
Key Recommendations
Surgical Intervention for Severe Comorbidities: Consider adrenalectomy in patients with uncontrolled hypertension, glucose intolerance, and dyslipidemia despite medical therapy (Evidence: Strong 1).
Biochemical Confirmation: Use 24-hour urinary free cortisol and low-dose dexamethasone suppression test for definitive diagnosis (Evidence: Strong 1).
Comprehensive Metabolic Monitoring: Regularly assess blood pressure, glucose levels, and lipid profiles post-diagnosis and treatment (Evidence: Moderate 1).
Mineralocorticoid Antagonists for Hypertension: Initiate spironolactone for managing hypertension and hypokalemia (Evidence: Moderate 1).
Glucose-Lowering Therapy: Implement metformin as first-line therapy for insulin resistance (Evidence: Moderate 1).
Lipid Management: Use statins to control dyslipidemia (Evidence: Moderate 1).
Post-Surgical Monitoring: Regular follow-up for adrenal insufficiency and metabolic parameters post-adrenalectomy (Evidence: Moderate 1).
Multidisciplinary Care: Involve endocrinologists, cardiologists, and metabolic specialists for complex cases (Evidence: Expert opinion 1).
Genetic Counseling: Offer genetic counseling for patients with suspected hereditary forms (Evidence: Expert opinion 1).
Pregnancy Management: Tailor glucocorticoid therapy carefully during pregnancy to balance maternal and fetal health (Evidence: Expert opinion 1).References
1 Zhou H, Zhang P, Yin Y, Liu L, Li J, Xu H et al.. Long-term cardiometabolic outcomes of primary bilateral macronodular adrenal hyperplasia. Journal of endocrinological investigation 2025. link